INTRODUCTION
The effective delivery of therapeutic peptides out of the blood to specific extravascular targets remains a major obstacle in the use of these agents in the treatment of disease and underscores the need for understanding the fundamental mechanisms by which macromolecules distribute into and across tissue barriers. Due to the unique properties of the endothelium lining the microvasculature of the brain in particular, the potential treatment of central nervous system disorders with peptides presents a significant challenge (5) . This thin, continuous nonfenestrated endothelium with tight intercellular junctions is referred to as the blood-brain barrier (BBB) (5, 8, 24) . Along with tight junctions, the cells also have few pinocytic vesicles, a complex glycocalyx, and significant metabolic capacity.
These characteristics make the BBB a very selective layer that excludes most water-soluble substances, including peptides, from entering the central nervous system from the blood (3, 5) .
Angiotensin II (Ang II) is an endogenous octapeptide that produces a number of physiological actions as a potent vasoconstrictor, stimulator of the release of cardiovascular regulators (e.g., endothelin and prostaglandins), neurotransmitter, and vascular cell growth promoter (22, 25, 38) . A recent study indicates that Ang II triggers internalization-recycling processes that seem to be a fundamental part of the Ang II type AT 1 receptor transduction mechanism (26) . In addition, receptormediated endocytosis of Ang II itself occurs in a number of different cell types (6, 17, 19, 34, 36) and does undergo transcytosis across peripheral endothelial cells (18) . Moreover, the in vivo demonstration of receptor-mediated uptake of Ang II by endothelial cells has prompted a hypothesis that internalization of Ang II is a physiological mechanism for clearance and protection of the peptide from endothelial peptidases (35) .
Previous work in our laboratory established that Ang II has specific binding sites on primary cultures of bovine brain microvessel endothelial cells (BMECs). Ang II also has typical biological effects Polycarbonate membranes (13 mm diameter; pore size 0.4 µm) were placed into 100 mm tissue culture dishes and coated with rat-tail collagen and bovine fibronectin. BMECs were grown to confluent monolayers, as determined by inspection of the areas around the membranes using an inverted microscope. The basolateral side of the cells was defined as the side facing the collagen matrix. After confluent monolayers were formed, the membranes were placed in a horizontal Side-bi-Side™ diffusion apparatus (Crown Glass, Inc., Somerville, NJ) for transendothelial permeability studies. The area of the diffusion membrane was 0.636 cm 2 . The donor and receiver chambers were filled with 3.0 ml of culture medium and the temperature was maintained with an external circulating water bath. The contents of each chamber were stirred with Teflon coated magnetic stir bars at a speed of 600 r/min driven by an external drive console (Crown Glass, Inc.).
The apical-to-basolateral permeation of [ 3 H]-Ang II was studied for 2 hours at 4°C and 37°C across confluent monolayers and at 37°C across collagen-coated membranes. The concentrationdependence of permeation was studied by adding to each donor chamber an aliquot of unlabeled Ang II mixed with [ 3 H]-Ang II. An aliquot of 25 µl was removed from the donor chamber to be assayed for initial donor concentration. Sample aliquots of 100 µl were removed from the receiver chamber at various times and the volume was replaced with fresh culture medium. The samples were placed in a scintillation vial with 10 ml of scintillation cocktail and assayed by scintillation spectrometry. The flux was determined by plotting pmoles versus minutes.
The apical-to-basolateral and the basolateral-to-apical permeation of 3 nM [ 3 H]-Ang II was studied at 37°C. Samples were taken as described above. The flux was determined by plotting pmoles Ang II appearing in the receiver chamber versus minutes. The apparent permeability coefficient was calculated using the equation: P = Flux / (A*C Do ) Rose donor chamber alone and samples were taken for 30 minutes from the receiver chamber. After the initial 30 minutes, an unlabeled peptide was added to the donor chamber and the transport was followed for 60 additional minutes. Samples were taken as described above. The flux was determined by plotting pmoles versus minutes. The apparent permeability coefficient was calculated using the equation described above. Rose were incubated at 37°C for 90 minutes. After the incubation, the monolayers were quickly rinsed three times with 4°C culture medium and solubilized as described above. The lysate from each well was collected, placed in a scintillation vial with 10 ml of scintillation cocktail, and assayed with a Beckman LS 6800 scintillation counter.
The transport of a pulse of [ 3 H]-Ang II alone was monitored for 30 minutes at 37°C as described above. After the 30 minute sample was removed, an endocytic inhibitor (i.e., 25 µM chloroquine or 10 µM monensin or 25 µM phenylarsine oxide) was added to the donor chamber and Ang II transport was followed for an additional 60 minutes. Apparent permeability coefficients for Ang II in the presence of the inhibitor were calculated as described above.
Statistical analysis
The comparison between mean values within each experimental series was performed by oneway analysis of variance using Dunnett's test to compare several treatments against a control. The amount of Ang II internalized was found by subtracting the value at 4°C from the value at 37°C, giving a value of 1.4 x 10 -12 moles (i.e., approximately 0.05% of the pulse) at 20 minutes, consistent with earlier work in our laboratory (12) . By contrast, the apical-to-basolateral permeation of Ang II across BMEC monolayers found to increase linearly with time over a two hour period. Figure The concentration dependence of Ang II transport in the apical-to-basolateral direction was performed at 37°C. Similar data was collected at 4°C, was subtracted from the 37°C data, and the difference plotted as shown in Figure 2 . The resulting curve indicated that Ang II transport across BMEC monolayers was a saturable process with a K m of 1.7 nM. At Ang II concentrations above the saturation point or plateau (>20 nM), peptide transport was found to again increase rapidly and linearly with increasing concentrations (data not shown). transport by approximately 30% (data not shown).
RESULTS
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As illustrated in Figure 5A , a 10 nM concentration of each of the Ang II fragments increased the transport of a pulse of [ by Speth and Harik (30) for Ang II binding to canine microvessels. In the earlier work, we demonstrated that Ang II exposure (i.e., 1 to 100 nM) produced a concentration-dependent decrease in the permeability of paracellular markers, fluorescein, molecular weight 376, and a fluorescein isothiocyanate-conjugated dextran, molecular weight of 4000 (13) . Therefore, while the flux of Ang II itself increases with increasing concentration, the paracellular permeability of the monolayers decreases with increasing concentration of the peptide. Therefore, we believe we have established that Ang II processing across BMEC monolayers occurred through a transcellular pathway.
Saturable, receptor-mediated endocytosis of Ang II has now been described in a number of cell types (6, 17, 19, 34, 35) . Specifically in endothelia, the absence of significant degradation of internalized Ang II has now been confirmed by both in vitro and in vivo studies. In our laboratory, three separate analytical systems, TLC (12), HPLC with electrochemical detection (28) , and HPLC with fluorescence detection (2) , have demonstrated that Ang II remains intact under the conditions of both the internalization and transport studies described in this report. Reports for peripheral endothelia (18) and proximal tubule epithelia (6) have also provided observations on the saturable transcellular transport of intact Ang II. However, these in vitro observations also fully support the recent van Kats et al. (35) report which indicated that in vivo, endothelial cell clearance of Ang II through an AT 1 receptormediated process seems to serve to protect the peptide from endothelial cell peptidases.
The uptake and transport of radiolabeled Ang II was found to be significantly inhibited by the addition of nM concentrations of unlabeled Ang II or the Ang II peptide antagonist sarathrin. These findings were in good agreement with similar studies with other cell types (6, (17) (18) (19) 34, 36) . At concentrations above the plateau (>20 nM), we observed Ang II transport to increase linearly with increasing concentrations (data not shown). This phenomenon is seen with many receptor-mediated endocytic processes where the molecule exhibits an affinity for the endothelial plasma membrane (37) .
At lower concentrations, the molecule will exhibit endocytic rates that are dependent upon the number and Ang II were found to have opposite effects on cerebral blood flow, with Ang II decreasing blood flow and Ang II-(3-8) increasing blood flow (16) . Ang II-(3-8) was also implicated as a vasodilator in rat cerebral arteries (15) . Considering the disparate actions and affinities of the Ang II fragments for the AT 1 receptor, we suggest that the internalization and transport process we observed here were specific to the parent Ang II and the AT 1 receptor. In part this supposition is based on our recent work (27) which demonstrated that an AT 2 antagonist did not inhibit the permeation of Ang II across the BMEC monolayers. That work also established with immunoblots, expression of a membrane-associated AT 1 receptor (27) . Unfortunately, antibodies do not currently exist for the other receptors. The Ang II fragments may either interact with other binding sites that indirectly regulate endocytic processes of BMECs or, alternatively, the fragments may displace Ang II from other non-AT 1 binding sites, providing more Ang II for specific internalization or transport pathways. Future work will be directed at defining the role of the fragments in binding, controlling fluid-phase endocytosis, and other biological functions in the BMECs.
Receptor-mediated endocytosis and transcytosis as mechanisms for Ang II processing by BMECs was supported by our observations that known endocytic inhibitors, monensin and phenylarsine oxide both inhibited Ang II internalization by BMECs. Phenylarsine oxide also significantly inhibited the transport of Ang II across the BMEC monolayers while monensin and chloroquine had little or no effect on peptide transport. Phenylarsine oxide has been shown to consistently inhibit, at least in part, Ang II internalization and transport in other studies (6, 17) and was supported by our observations. Monensin has been shown to effectively inhibit Ang II AT 1 receptor internalization and recycling back to the cell surface (17, 26) and chloroquine inhibits Ang II dissociation from cells (17) . We did not look at Ang II return to the culture medium in this study and chloroquine may, in fact, have had effects on this process by BMECs. We did previously find that chloroquine inhibited Ang II-stimulated fluid-phase endocytosis by BMECs (11) and may be an indication that only certain endosomal pathways of these cell were sensitive to the drug. Although the concentrations of inhibitors used here were within ranges known to affect the internalization and transport of other receptors, the effects of these inhibitors generally differ from cell type to cell type. From earlier work we also know that the activity of apical membrane internalization-recycling activities by BMECs appeared to be quite active while the contributions of transcellular transport were limited (14, 23) . The differences between effects of the endocytic inhibitors on internalization and transport could also be due to the differences between experimental conditions in uptake and transport studies. For the internalization studies, Ang II and the inhibitors were added at the same time whereas in the more dynamic transport studies, the inhibitor was added after Ang II was already being processed for transcytosis by the BMECs. Therefore, in the transport studies the more active internalization process allowed Ang II to enter the cell and the intracellular sorting process.
Consequently, much of the Ang II transport observed in the presence of the inhibitors was peptide that may have entered the cells prior to addition of the agent. Irregardless, the sensitivity of the internalization and transport of Ang II to monensin and phenylarsine oxide affirmed a role for endosomal processing of the peptide and was consistent with reports for other cell types exhibiting receptor-mediated endocytosis (17) (18) (19) 34, 36) .
In conclusion, the permeation of Ang II across BMEC monolayers was linear, concentrationdependent, saturable, tended to be polarized in the apical-to-basolateral direction, and was attenuated by endocytic inhibitors. This study forms the basis to further consider metabolically stable Ang II peptide analogs or Ang II receptor substrates as BBB transport vectors and further supports the role of the BBB as an active participant in regulating vascular levels of peptide hormones. 
